GLAXO — GlaxoSmithKline Pharmaceuticals Balance Sheet
0.000.00%
- IN₹464.66bn
- IN₹438.84bn
- IN₹37.49bn
- 95
- 12
- 75
- 69
Annual balance sheet for GlaxoSmithKline Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 11,372 | 28,309 | 16,541 | 18,568 | 24,981 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2,975 | 3,052 | 3,419 | 3,720 | 3,848 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 22,026 | 37,080 | 24,943 | 27,984 | 34,099 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,554 | 3,254 | 3,151 | 3,107 | 2,839 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 31,146 | 46,333 | 33,266 | 35,566 | 41,081 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 13,546 | 16,984 | 13,264 | 15,249 | 19,052 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 16,364 | 19,703 | 15,853 | 17,790 | 21,568 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 14,783 | 26,630 | 17,413 | 17,776 | 19,513 |
| Total Liabilities & Shareholders' Equity | 31,146 | 46,333 | 33,266 | 35,566 | 41,081 |
| Total Common Shares Outstanding |